ArticleJournal of virology2005
Leucine-specific, functional interactions between human immunodeficiency virus type 1 Nef and adaptor protein complexes.
Article in Journal of virology, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 38 citations in OpenAlex.
- Article
- Interaction of HIV-1 Nef protein with the host protein Alix promotes lysosomal targeting of CD4 receptor.The Journal of biological chemistry · 2014Article
- The frantic play of the concealed HIV envelope cytoplasmic tail.Retrovirology · 2013Review
- Minimotif Miner 3.0: database expansion and significantly improved reduction of false-positive predictions from consensus sequences.Nucleic acids research · 2012Article
- Trans-cellular introduction of HIV-1 protein Nef induces pathogenic response in Caenorhabditis elegans.PloS one · 2010Article
- An MHC-I cytoplasmic domain/HIV-1 Nef fusion protein binds directly to the mu subunit of the AP-1 endosomal coat complex.PloS one · 2009Article
- Nef-induced CD4 endocytosis in human immunodeficiency virus type 1 host cells: role of p56lck kinase.Journal of virology · 2009Article
- Human immunodeficiency virus type 1 Nef protein targets CD4 to the multivesicular body pathway.Journal of virology · 2009Article
- Human immunodeficiency virus type 1 Nef incorporation into virions does not increase infectivity.Journal of virology · 2009Article
- The AP-2 adaptor beta2 appendage scaffolds alternate cargo endocytosis.Molecular biology of the cell · 2008Article
- HIV-1 Nef: at the crossroads.Retrovirology · 2008Review
- Article
- Competition model for upregulation of the major histocompatibility complex class II-associated invariant chain by human immunodeficiency virus type 1 Nef.Journal of virology · 2008Article
- A diacidic motif in human immunodeficiency virus type 1 Nef is a novel determinant of binding to AP-2.Journal of virology · 2008Article
- Cooperative binding of the class I major histocompatibility complex cytoplasmic domain and human immunodeficiency virus type 1 Nef to the endosomal AP-1 complex via its mu subunit.Journal of virology · 2008Article
- Sequence of human immunodeficiency virus type 1 (HIV-1) Gag localization and oligomerization monitored with live confocal imaging of a replication-competent, fluorescently tagged HIV-1.Journal of virology · 2007Article
- The gamma/sigma1 and alpha/sigma2 hemicomplexes of clathrin adaptors AP-1 and AP-2 harbor the dileucine recognition site.Molecular biology of the cell · 2007Article
- Downregulation of CD4 by human immunodeficiency virus type 1 Nef is dependent on clathrin and involves direct interaction of Nef with the AP2 clathrin adaptor.Journal of virology · 2007Article
- Interactions between Nef and AIP1 proliferate multivesicular bodies and facilitate egress of HIV-1.Retrovirology · 2006Article
- Modulation of cellular protein trafficking by human immunodeficiency virus type 1 Nef: role of the acidic residue in the ExxxLL motif.Journal of virology · 2006Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 2 countries.
Funding
Abstract
The human immunodeficiency virus type 1 virulence protein Nef interacts with the endosomal sorting machinery via a leucine-based motif. Similar sequences within the cytoplasmic domains of cellular transmembrane proteins bind to the adaptor protein (AP) complexes of coated vesicles to modulate protein traffic, but the molecular basis of the interactions between these motifs and the heterotetrameric complexes is controversial. To identify the target of the Nef leucine motif, the native sequence was replaced with either leucine- or tyrosine-based AP-binding sequences from cellular proteins, and the interactions with AP subunits were correlated with function. Tyrosine motifs predictably modulated the interactions between Nef and the mu subunits of AP-1, AP-2, and AP-3; heterologous leucine motifs caused little change in these interactions. Conversely, leucine motifs mediated a ternary interaction between Nef and hemicomplexes containing the sigma1 plus gamma subunits of AP-1 or the sigma3 plus delta subunits of AP-3, whereas tyrosine motifs did not. Similarly, only leucine motifs supported the Nef-mediated association of AP-1 and AP-3 with endosomal membranes in cells treated with brefeldin A. Functionally, Nef proteins containing leucine motifs down-regulated CD4 from the cell surface and enhanced viral replication, whereas those containing tyrosine motifs were inactive. Apparently, the interaction of Nef with the mu subunits of AP complexes is insufficient for function. A leucine-specific mode of interaction that likely involves AP hemicomplexes is further required for Nef activity. The mu and hemicomplex interactions may cooperate to yield high avidity binding of AP complexes to Nef. This binding likely underlies the unusual ability of Nef to induce the stabilization of these complexes on endosomal membranes, an activity that correlates with enhancement of viral replication.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.